Medical Developments International (MVP) Stock Overview
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MVP Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Medical Developments International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.66 |
| 52 Week High | AU$0.94 |
| 52 Week Low | AU$0.40 |
| Beta | 1.49 |
| 1 Month Change | 12.93% |
| 3 Month Change | 7.82% |
| 1 Year Change | 45.56% |
| 3 Year Change | -62.14% |
| 5 Year Change | -87.59% |
| Change since IPO | 36.46% |
Recent News & Updates
There Is A Reason Medical Developments International Limited's (ASX:MVP) Price Is Undemanding
Aug 08
Medical Developments International (ASX:MVP) Is In A Strong Position To Grow Its Business
Jul 18Recent updates
There Is A Reason Medical Developments International Limited's (ASX:MVP) Price Is Undemanding
Aug 08Medical Developments International (ASX:MVP) Is In A Strong Position To Grow Its Business
Jul 18
Targeted Pricing And Penthrox Expansion Will Broaden International Reach
Targeted pricing and efficiency programs are improving margins, expected to enhance earnings and net margins over the next few years.Medical Developments International Limited (ASX:MVP) Held Back By Insufficient Growth Even After Shares Climb 33%
May 07Medical Developments International (ASX:MVP) Is In A Strong Position To Grow Its Business
Apr 18Take Care Before Jumping Onto Medical Developments International Limited (ASX:MVP) Even Though It's 27% Cheaper
Mar 16Benign Growth For Medical Developments International Limited (ASX:MVP) Underpins Its Share Price
Jan 30Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump
May 13Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?
May 03Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge
Mar 11Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward
Jan 16Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?
Jan 03Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Aug 09We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate
Apr 24Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Jul 04Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates
Mar 04Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates
Mar 05If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns
Feb 07Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)
Dec 16Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Dec 10
Shareholder Returns
| MVP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -3.7% | 16.0% | 2.3% |
| 1Y | 45.6% | -7.7% | 10.1% |
Return vs Industry: MVP exceeded the Australian Pharmaceuticals industry which returned -19.1% over the past year.
Return vs Market: MVP exceeded the Australian Market which returned 8.8% over the past year.
Price Volatility
| MVP volatility | |
|---|---|
| MVP Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 19.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MVP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MVP's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Brent MacGregor | medicaldev.com |
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures.
Medical Developments International Limited Fundamentals Summary
| MVP fundamental statistics | |
|---|---|
| Market cap | AU$73.79m |
| Earnings (TTM) | AU$94.00k |
| Revenue (TTM) | AU$39.06m |
Is MVP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVP income statement (TTM) | |
|---|---|
| Revenue | AU$39.06m |
| Cost of Revenue | AU$9.63m |
| Gross Profit | AU$29.43m |
| Other Expenses | AU$29.33m |
| Earnings | AU$94.00k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.00083 |
| Gross Margin | 75.35% |
| Net Profit Margin | 0.24% |
| Debt/Equity Ratio | 0% |
How did MVP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 10:23 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medical Developments International Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Martyn Jacobs | Bell Potter |
| Martyn Jacobs | Canaccord Genuity |